Objective: To verify whether platelet responsiveness to leptin is associated with metabolic syndrome risk factors. Design: Cross-sectional study. Subjects: We studied 169 consecutive patients, mean age ¼ 43.679.9 years, with overweight (N ¼ 57) or obesity (N ¼ 112). Measurements: Cluster analysis was used to generate three clusters based on platelet responsiveness to increasing doses of leptin. Profiles of metabolic syndrome risk factors of the three clusters were compared by discriminant analysis. Results: Platelet responsiveness to leptin was absent in cluster 1, whereas cluster 3 had the greatest platelet aggregation response to leptin pre-incubation. Plasma leptin levels significantly decreased from cluster 1 to cluster 3 in both gender. Patients in cluster 2 had an intermediate profile of leptin responsiveness. Highest body mass index (BMI) values were more frequent in non-responders, whereas the prevalence of high waist circumference, as well as hypertriglyceridemia and hypertension, increased with increasing responsiveness to leptin from cluster 1 to cluster 3. Pattern of metabolic syndrome risk factors qualified as group specific in 69.0% of the cluster 1, 54.9% of the cluster 2 and 55.8% of the cluster 3. Circulating leptin, waist circumference, plasma triglycerides and BMI defined distinctive patterns of metabolic syndrome risk factors in the clusters. Conclusions: In overweight and obese outpatients, metabolic syndrome risk factors parallel to some extent platelet responsiveness to leptin. Such a correlation involves plasma leptin levels, waist circumference, plasma triglycerides and BMI, and may contribute to the excess risk of cardiovascular events in overweight and obese patients.
Introduction
Obesity is known to be associated with accelerated atherothrombosis and increased incidence of cardiovascular morbidity and mortality. Several evidences demonstrate that metabolic disorders that frequently accompany excess body weight, such as insulin resistance, hypertension, hypertriglyceridemia and decreased high-density lipoprotein (HDL) cholesterol, promote the progression of atherosclerosis in obese patients. [1] [2] [3] Additionally, altered hemostatic balance also may contribute to the excess risk of acute cardiovascular events in obese individuals. 4, 5 Leptin, the product of the ob gene, 6 is a protein secreted mainly by the adipose tissue, which signals the size of energy stores to the central nervous system modulating the activity of hypothalamic centers involved in the regulation of food intake and energy balance. 7 Although leptin's major role seems to be in the regulation of body weight and energy metabolism, several evidences suggest that this hormone could be involved in other pathophysiological mechanisms, such as immune function, angiogenesis, bone formation and fertility, and the expression of leptin receptor has been demonstrated in a variety of tissues. [8] [9] [10] [11] [12] [13] The long form of leptin receptor (ObRb) has been found on platelet membrane, 14 and it has been demonstrated that leptin-deficient ob/ob mice, 15, 16 and wild-type mice treated with a leptin-neutralizing antibody, 17 develop unstable thrombi and an attenuated thrombotic response to arterial injury, and they exhibit a defective platelet aggregation. Leptin also promotes thrombosis in the mouse, and it potentiates the aggregation of murine platelets in vitro in a leptin receptor-dependent manner. 15 Leptin also enhances the aggregation of human platelets, 14, [18] [19] [20] but it has recently been reported that the response varies significantly between donors, with platelets from some donors consistently responding to leptin (responders) and those from other donors never responding (non-responders). Although platelets from both responders and non-responders express the signaling form of the leptin receptor, platelets from responder donors express higher levels of this receptor than platelets from non-responders. 21 However, whether the platelet responsiveness to leptin really corresponds to a high-risk phenotype remains to be established. Indeed, the platelet aggregation response to leptin was blunted in patients with overweight or obesity in a former study, 19 thus suggesting that platelet from obese donors may be resistant to the pro-aggregating action of leptin. The metabolic syndrome is a constellation of interrelated risk factors that appear to directly promote the development of atherosclerotic cardiovascular disease. 22, 23 The metabolic syndrome is also associated with a hypercoagulable state, consisting of increased levels of clotting factors (tissue factor, factor VII and fibrinogen) as well as inhibition of the fibrinolytic pathway (increased plasminogen activator inhibitor-1 and decreased tissue plasminogen activator activity). Furthermore, the association of metabolic syndrome with endothelial dysfunction and dyslipidemia triggers platelet aggregability, thus further increasing the risk of thrombotic events. 24 Thus, the study of the relationship between platelet responsiveness to leptin and metabolic syndrome is of particular interest.
In the present study, we tested the hypothesis that platelet responsiveness to leptin is associated with metabolic syndrome variables in an attempt to verify whether responders are characterized by a typical clinical/metabolic high-risk phenotype.
Methods

Subjects
Our series consisted of 169 informed consent patients with overweight or obesity consecutively admitted to the Outpatient's Service for Prevention and Treatment of Obesity at the University Hospital of Messina, Italy. Subjects who were receiving treatment with antithrombotic agents (including aspirin), contraceptive or hormonal replacement therapy were excluded from the study. Diagnostic criteria for metabolic syndrome were those suggested by the US National Cholesterol Education Program -Adult Treatment Panel III (NCEP ATP-III): waist circumference X102 cm for men or X88 cm for women; plasma triglycerides X150 mg/dl; HDL cholesterol o40 mg/dl for men and o50 mg/dl for women; blood pressure X130/85 mm Hg; fasting plasma glucose 46.1 mmol/l. 23 The study protocol was approved by the local ethical committee.
Measurements
Body height was measured without shoes to the nearest 0.5 cm; body weight was measured without clothes to the nearest 0.1 kg; body mass index (BMI) was calculated as weight/height 2 (kg/m 2 ). Waist circumference was measured midway between the lower rib margin and the iliac crest. Arterial blood pressure was measured with a Riva-Rocci sphygmomanometer (Zenith, Rome, Italy). Blood pressure values were taken with patient at rest in supine position from at least 5 min. The first measurement was excluded and the average of the following three measurements, taken at 3-min intervals was considered. Fasting plasma glucose (AutoAnalyzer, Beckman, Milan, Italy), HDL cholesterol, triglycerides (CHOP-PAP procedure, Boehringer Biochemia, Milan, Italy) and leptin (Human Leptin RIA kit, Linco Research Inc., St Charles, MO, USA) were measured for each patient enrolled.
Informations about the hormonal status of women (post-/ premenopausal) were also collected. Smoking habits and the use of antihypertensive, hypoglycemic and/or lipid-lowering drugs in the month before the enrollment in the study were considered in the analysis.
Leptin-dependent platelet aggregation
Platelet aggregation response to leptin was measured as described previously. 19, 20 Briefly, after an overnight fasting, a venous blood sample was obtained from each patient in the supine position from the cubital vein of the arm using a cannula that had been placed 30 min before sampling to avoid the stress of venipuncture, and maintained by slow infusion of saline solution (0.5 ml/min). Blood samples (25 ml) were collected in a conical polipropylene tube containing 3.33 ml/l of citric acid/sodium citrate/dextrose (ACD) (consisting of 64 mmol/l citric acid, 85 mmol/l sodium citrate and 111 mmol/l dextrose). Platelet-rich plasma (PRP) was obtained by centrifugation at 800 g for 20 min at 41C. The PRP was centrifugated at 2000 g at 41C to form a soft platelet pellet, resuspended in N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid-potassium hydroxide (HEPES) Tyrode's buffer (HEPES-buffered saline (HBS)) consisting of 145 mmol/l NaCl, 5 mmol/l KCl, 0.5 mmol/l NaH 2 PO 4 , 1 mmol/l MgSO 4 , 5.5 mmol/l glucose, 3.0 mg/l bovine serum albumin, 10 mmol/l HEPES, pH 7.4, and washed once. Centrifugation was performed at 41C in order to minimize spontaneous platelet activation. 25 Platelets were counted (Coulter International Corporation, Miami, FL, USA) and resuspended in HBS buffer at a concentration of 0.5-1 Â 10 8 platelets/ml. Aliquots (0.4 ml) containing 1 mmol/l CaCl 2 were dispensed into Metabolic syndrome and platelet response to leptin F Corica et al aggregometer cuvettes. Aliquot of HBS was used as a reference to indicate 100% in optical aggregation experiments. Aggregation response to agonist was optically monitored (PACKS4, Helena Laboratories, Beaumont, TE, USA). Light transmission was continuously compared with that from the HBS. Platelet aggregation was expressed as % maximal aggregation.
To study leptin effects on agonist-induced aggregation, 0.4 ml of platelet suspension was pre-incubated with leptin 5, 10, 25, 50 or 100 ng/ml (Linco Research Inc., St Charles, MO, USA) for 5 min, and then stimulated with adenosine diphosphate (ADP) (Sigma Chemical Co., St Louis, MO, USA) 2 mmol/l (Sigma Chemical Co., St Louis, MO, USA).
Analytic approach
Patients were aggregated in three clusters by K-means cluster analysis on the basis of their % maximal aggregation response to ADP 2 mmol/l after pre-incubation with increasing doses of leptin. Because of the skewed distribution of % maximal aggregation, data were log-transformed. Cluster analysis allows to group patients within clusters having a distinctive platelet aggregation profile in response to rising doses of leptin. The squared Euclidean distances were computed to assess dissimilarity or distance between patients in the multidimensional space defined by % maximal aggregation. The lower the distance the greater the affinity between patients, that is, between their platelet aggregation profiles.
The model was forced to generate three clusters because the only study comparing responders and non-responders was carried out with platelets from lean donors. 21 Thus, any a priori definition of responsiveness patterns by platelets from obese donors based on the available knowledge may limit our understanding of the association between platelet response to leptin and metabolic syndrome risk factors. Furthermore, we previously reported that overweight and obesity are associated with a continuous progressive reduction of platelet leptin sensitivity. 19 Therefore, we judged that forcing the model to generate three clusters might be a good strategy according to the hypothesis that an intermediate level of platelet responsiveness would exist between nonresponders and responders. Based upon the agglomerative clustering method, patients were segregated into three clusters according to the distances measured, that is, the degree of similarity between and among their platelet aggregation profiles. The final objective of the analysis is to obtain clusters as distinct as possible by minimizing variability in platelet aggregation response within clusters and to maximize variability between clusters. 26 Therefore, we compared demographic and metabolic characteristics of the three clusters by analysis of variance one-way with Scheffè post hoc test, or cross-tabulation with Pearson's w 2 . Then, a discriminant analysis of age, gender and metabolic profiles of clusters was performed. This analysis aimed at identifying cluster-specific metabolic patterns corresponding to the most common combinations of metabolic syndrome variables within each cluster and, then, cross-tabulates individual metabolic patterns versus clusterspecific patterns. The higher the concordance between actual cluster membership, as resulting from the cluster analysis, and predicted cluster membership, as resulting from individual metabolic patterns, the greater the specificity of the metabolic profile of the corresponding cluster. We computed the Wilk's lambda coefficient to test the null hypothesis, that is, that groups did not differ in the means of the discriminating functions. The Box's M coefficient was computed to assess the risk of misclassification by the discriminant function. Individual metabolic syndrome variables, which were more useful for characterizing and discriminating clusters were identified and ordered on the basis of their standardized coefficients. The pooled within-groups correlation matrix was used to check for multicollinearity. 27 Kappa statistic was used to verify the agreement between actual and discriminant-predicted cluster membership. All analyses were performed using SPSS V10.0 (SPSS Inc., Chicago, IL, USA).
Results
Patients enrolled in the study had mean age 43.679.9 years. The majority of patients were female (66.9%), and 112 out of 169 patients had a BMI greater or equal to 30 kg/m 2 . The most frequently observed metabolic syndrome risk factors were low HDL cholesterol (47.9%) and high waist circumference (46.7%), followed by high blood pressure (38.5%), hypertriglyeridemia (35.5%) and hyperglycemia (33.7%). Postmenopausal state was present in 37.2% of enrolled women.
The % maximal aggregation response to pre-incubation with increasing doses of leptin in the three clusters identified is reported in Table 1 . Platelets from patients in cluster 1 (non-responders) had no response to leptin pre-incubation, and % maximal aggregation was similar to that obtained with ADP 2 mmol/l alone (log-transformed % maximal aggregation ¼ 0.470.3). At the opposite extreme, platelets from patients in cluster 3 (high-responders) had a very high Plasma leptin concentration was higher in non-responders when compared with mid-and high-responders, and gender did not affect these results (Figure 1) . Age, gender, smoking habits and postmenopausal state did not distinguish any of the three clusters. Overweight patients (BMI ¼ 25-29.9 kg/m 2 ) were more frequent in highresponders, whereas very obese individuals (BMI ¼ 35 kg/m 2 or more) were more frequent in non-responders. On the contrary, the prevalence of high waist circumference increased with increasing responsiveness to leptin from cluster 1 to cluster 3. High plasma tryglicerides, HDL cholesterol and blood pressure were more frequent in mid-and highresponders with respect to non-responders. Plasma glucose was not significantly associated to the degree of platelet responsiveness to leptin, as was the use of antihypertensive, hypoglycemic and lipid-lowering drugs (Table 2) .
Discriminant analysis identified two discriminant functions, the former of which was highly significant (Table 3) . A high concordance between actual and predicted cluster membership was observed in cluster 1 (non-responders). Concordance was fair for clusters 2 and 3 (mid-and highresponders, respectively): 10.9% of patients in cluster 2 and 21.5% of patients in cluster 3 were classified as functionally belonging to cluster 1 ( Table 4 ). The pooled within-groups correlation matrix showed that the coefficient for the relationship between BMI and waist circumference was equal to 0.20. Kappa coefficient was equal to 0.41, which correspond to a fair to moderate overall agreement between actual and predicted cluster membership. When we excluded BMI and waist circumference from the discriminant model, only 44.4% of cases were correctly classified. The corresponding figures obtained by including BMI alone, waist circumference alone or both variables were 52.6, 53.8 and 60.0%, respectively.
The highly significant Box's M coefficient showed that the risk of misclassification by the discriminant function was very low, that is, the definition of individual profiles of platelet responsiveness to leptin was highly reliable. Among variables considered in the analysis, plasma leptin concentrations, waist circumference, plasma tryglicerides and BMI significantly contributed to the discriminant function 1 (Table 5 ). When BMI was excluded from the analysis, the coefficient for waist circumference slightly increased from 0.427 to 0.479. Age, gender, smoking habits, postmenopausal state, fasting plasma glucose and use of antihypertensive, hypoglycemic or lipid-lowering agents did not contribute to either function 1 or 2.
Discussion
The novel finding of the present study is the demonstration that overweight or obese patients can be clustered on the basis of the degree of their platelet responsiveness to leptin, and that metabolic syndrome risk factors may contribute to define the clinical profile of responders.
Both responsive and non-responsive platelets from healthy donors only express the long signaling form of the ObRb, whereas neither express the short non-signaling form. A reduced expression of the ObRb on platelet membrane and/ or a lower affinity variant of the ObRb could be invoked to explain the non-responsiveness to leptin. 21 Our results Figure 1 Plasma leptin levels in the three clusters.
Metabolic syndrome and platelet response to leptin F Corica et al extend those reported by Giandomenico et al. 21 by demonstrating the existence of three clusters of overweight or obese patients with different degrees of platelet responsiveness to leptin. Furthermore, circulating leptin and selected metabolic risk factors could distinguish clusters, that is, contributed to define distinctive clinical patterns associated with platelet responsiveness to leptin. Increased waist circumference is strongly associated with decreased insulin sensitivity, 28 and abdominal adiposity is one of the most important risk factors in the metabolic syndrome. 22, [28] [29] [30] Under physiological conditions, insulin is known to decrease platelet aggregability through reduction of platelet responses to ADP and thrombin. 31, 32 Platelets from insulin-resistant subjects have reduced sensitivity to the antiaggregating effects of insulin, 33 and it can be Metabolic syndrome and platelet response to leptin F Corica et al hypothesized that a greater insulin resistance in patients with a more pronounced abdominal adiposity may contribute to the profile of platelet responsiveness to leptin in our study. Dyslipidemia can also contribute to increase platelet activation. 34 Plasma triglycerides have been shown to increase both platelet aggregability and the incidence of venous thromboembolism, whereas these detrimental effects are reversed by HDL cholesterol. 35 Because the metabolic syndrome is characterized by an imbalance of increased oxidized low-density lipoprotein (LDL) and decreased HDL cholesterol levels, this is likely to result in hyperaggregation. 36 Another feature of dyslipidemia in the metabolic syndrome is a significant increase in very-low-density lipoprotein (VLDL) levels, which have been shown to induce platelet thromboxane A2 production through binding of CD36 ligand. 37 CD36 ligand facilitates the supply of fatty acids for platelet thromboxane production, which stimulates collagen-induced platelet aggregation. 38 The pattern of BMI and plasma leptin distribution among clusters deserves particular attention. Indeed, highest BMI values were more frequently segregated into the cluster 1, that is, non-responders cluster, and circulating leptin was also a negative correlate of the outcome. This finding strongly suggests that leptin sensitivity is needed for leptin to enhance platelet aggregation response to subthreshold doses of the agonist. Leptin-induced platelet aggregation is blunted, but not completely abolished, in overweight and obese patients when compared to normal weight subjects, and this observation suggests that leptin receptor on platelet membrane may represent a site of leptin resistance in human obesity. 19 These findings have been recently extended by
Canavan et al. 39 by demonstrating that normal weight subjects undergoing complete caloric deprivation had greater sensitivity in hemostatic responses to leptin. The present study further confirms the existence of a differential sensitivity to the pro-thrombotic action of leptin effect based on total adiposity, and suggests the hypothesis that platelet resistance to leptin in overweight or obese patients could represent a finalistic protective mechanism against the excess pro-thrombotic stimulation that would be produced by obesity-related hyperleptinemia. The highest circulating leptin concentrations in patients belonging to cluster 1 support this hypothesis. The fact that the association between platelet responsiveness to leptin and BMI is opposite to that with waist circumference could be an effect of multicollinearity rather than an indicator of a biological relationship between anthropometric variables and platelet responsiveness to leptin. However, the low correlation coefficient for the relationship between BMI and waist circumference in the within-groups correlation matrix seems to deny this hypothesis. Therefore, a possible explanation for this apparent discrepancy should take into account the contribution of circulating leptin to the discriminant function, that is, to the responsiveness of platelets to leptin. Indeed, it is well known that plasma leptin concentrations are related to total fat mass, and are not affected by the distribution of fat between peripheral and abdominal stores. [40] [41] [42] Thus, highest BMI values and leptin concentrations contribute to define the clinical and metabolic profile of the cluster with the lower sensitivity to leptin. On the contrary, highest waist circumference values, as a marker of insulin resistance, 28 contribute to define the clinical profile of responsive patients. Such an explanation may also be involved in the lower prevalence of metabolic syndrome risk factors other than BMI in cluster 1.
Although high blood pressure and low HDL cholesterol were more frequent among patients in clusters 2 and 3, these risk factors did not contribute to discriminate the clinical profile of leptin sensitivity. Leptin-mediated sympatho-activation is recognized as one of the major mechanisms leading to the development of obesity-induced hypertension. Obesity is generally associated with resistance to the anorexic and weight-reducing actions of leptin, 43 and about one-third of patients in our study were completely resistant to the prothrombotic action of the hormone. However, recent evidences have shown preservation of sympatho-excitatory and pressor actions of leptin in obesity, 44 and this selective leptin resistance may help to explain why high blood pressure did not contribute to discriminate clusters in our study. Finally, the low discriminatory capacity of HDL cholesterol suggests that increasing oxidized LDL and VLDL, which are wellknown determinants of hyperaggregability in metabolic syndrome, 24,36 but were not measured in the present study, may contribute to leptin-dependent platelet aggregation more than HDL cholesterol depletion. Our findings do not prove that leptin-dependent platelet aggregation is causally related to metabolic syndrome risk factors. Indeed, both platelet responsiveness to leptin and metabolic syndrome could be different effects of the same disease status, that is, insulin resistance. However, it is conceivable that the coexistence of leptin responsiveness and selected metabolic risk factors could herald a welldefined high-risk profile in a population of overweight or obese outpatients, and further studies should be undertaken to clarify the prognostic significance of such an association.
Our study also has some limitations. Plasma insulin concentrations were not measured. Thus, the degree of insulin resistance and its contribution to our results cannot be exactly estimated. However, selected metabolic syndrome risk factors, such as waist circumference and triglycerides are strongly associated with reduced insulin sensitivity. 28 Furthermore, as suggested by results from univariate analysis, the relationship between clusters and some metabolic syndrome risk factors, such as waist circumference and HDL cholesterol, may be non-linear. This problem may have reduced the discriminatory capacity of these variables in our study. Finally, the cross-sectional design does not allow us to verify whether leptin-dependent platelet aggregation increases with weight loss, improvement of leptin sensitivity and reduced leptin levels. Although in normal weight subjects caloric deprivation produce a greater hemostatic Metabolic syndrome and platelet response to leptin F Corica et al responses to leptin, 39 this finding need to be prospectively replicated in overweight and obese patients.
In conclusion, our study shows that platelet aggregation responsiveness to leptin and metabolic syndrome are strictly related. Our study provides further support to the hypothesis that a direct adipocyte-platelet interaction may contribute to the excess risk of cardiovascular events in overweight and obese patients. On the basis of our and previous studies, it seems sensible to verify whether a distinctive pattern of platelet aggregation response to leptin characterizes patients carrying a particularly high risk for cardiovascular complications.
